D. Banerji

J. Ramsdell, L. Fish, M. Kavuru, 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma.

E. Kerwin, C. Laforce, W. Berger, 2005, The Journal of allergy and clinical immunology.

The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis.

D. Gentile, B. Angelini, David Skoner, 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Risk‐Benefit Value of Inhaled Glucocorticoids: A Pharmacokinetic/ Pharmacodynamic Perspective

S. Szefler, H. Derendorf, R. Nave, 2004, Journal of clinical pharmacology.

Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with the non-CFC propellant HFA-134a in patients with asthma. Azmacort HFA Clinical Study Group.

D. Banerji, T. Uryniak, R. Kane, 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Assessment of the Long-term Safety of Inhaled Ciclesonide on Growth in Children With Asthma

David Skoner, J. Maspero, D. Banerji, 2008, Pediatrics.

QVA149 compared with salmeterol/fluticasone (SFC) on exacerbations and its correlation with baseline blood eosinophils: A pooled analysis of LANTERN and ILLUMINATE

D. Price, J. Wedzicha, R. Fogel, 2015 .

Reply to Cooper et al.: The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease.

J. Wedzicha, N. Roche, C. Vogelmeier, 2017, American journal of respiratory and critical care medicine.

Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.

T. Casale, E. Bateman, S. Wenzel, 2006, Chest.

Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.

F. Patalano, D. Banerji, 2016, Respiratory medicine.

QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study

K. Hirata, Y. Fukuchi, Y. Minakata, 2013 .

Efficacy and safety of once-daily NVA 237 in patients with moderate-to-severe COPD : the GLOW 1 trial

K. Hirata, G. Ferguson, D. Banerji, 2012 .

Reply: What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease?

J. Wedzicha, N. Roche, C. Vogelmeier, 2017, American journal of respiratory and critical care medicine.

Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study

J. Wedzicha, N. Zhong, M. Ichinose, 2017, International journal of chronic obstructive pulmonary disease.

Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study.

J. Wedzicha, N. Roche, C. Vogelmeier, 2017, American journal of respiratory and critical care medicine.

Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus salmeterol/fluticasone (SFC): the FLAME study

A. Anzueto, K. Kostikas, R. Fogel, 2017 .

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.

J. Wedzicha, M. Decramer, D. Niewoehner, 2013, The Lancet. Respiratory medicine.

QVA149 versus glycopyrronium for COPD - authors' reply.

J. Wedzicha, M. Decramer, D. Niewoehner, 2013, The Lancet. Respiratory medicine.

A controlled trial of chlorofluorocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. Azmacort HFA Study Group.

D. Bernstein, M. Welch, D. Banerji, 1999, Chest.

QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study

J. Wedzicha, M. Decramer, J. Ficker, 2013 .

Once-Daily QVA149 Reduces Exacerbations and Improves Health Status in Comparison With Glycopyrronium and Tiotropium in Patients With Severe-to-Very Severe COPD: The SPARK Study

J. Wedzicha, J. Ficker, P. D’Andrea, 2013 .

Dual Bronchodilation With Once-Daily QVA149 Reduces Exacerbations, Improves Lung Function and Health Status Versus Glycopyrronium and Tiotropium in Severe-to-Very Severe COPD Patients: The SPARK Study

J. Wedzicha, T. Sandström, J. Ficker, 2013 .

QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study

J. Wedzicha, M. Decramer, J. Ficker, 2013 .

P236 Superior lung function with once-daily QVA149 translates into improvements in patient-reported breathlessness compared with placebo and tiotropium in COPD patients: the BLAZE study

D. Mahler, H. Worth, K. Kulich, 2013, Thorax.

Long-Term Safety of a Non-Chlorofluorocarbon- Containing Triamcinolone Acetonide Inhalation Aerosol in Patients with Asthma

H. Nelson, J. Petillo, D. Banerji, 2000 .

Safety and efficacy of NVA237 once daily in Japanese patients: The GLOW4 trial

T. Kawayama, Y. Fukuchi, D. Banerji, 2012 .

Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: The SHINE study

E. Bateman, N. Barnes, G. Ferguson, 2012 .

QVA149 administered once daily provides significant improvements in lung function over 1 year in patients with COPD: The ENLIGHTEN study

R. Dahl, K. Chapman, V. Alagappan, 2012 .

NVA237 Once Daily Provides Rapid And Sustained Bronchodilation In COPD Patients, With Efficacy Similar To Tiotropium: The GLOW2 Trial

E. Kerwin, J. Hébert, D. Banerji, 2012, ATS 2012.

The novel inhaled corticosteroid ciclesonide is efficacious and has a favorable safety profile in adults and adolescents with severe persistent asthma

W. Busse, M. Kaliner, D. Bernstein, 2005 .

Comparison of COPD Exacerbations With Once-Daily QVA149 Versus Twice-Daily Salmeterol/Fluticasone Combination: The ILLUMINATE Study

E. Bateman, C. Vogelmeier, D. Banerji, 2014 .

Once-Daily Dual Bronchodilation With QVA149 Reduces COPD Exacerbations: Results From the IGNITE Program

M. Fedele, D. Banerji, Hungta Chen, 2014 .

Cardio- and cerebro-vascular safety of QVA149: Results from a pooled analysis

N. Barnes, G. Ferguson, P. D’Andrea, 2013 .

Once-daily QVA149 has a good safety profile in patients with COPD

R. Dahl, C. Vogelmeier, T. Welte, 2013 .

Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study

C. Vogelmeier, R. Fogel, K. Chapman, 2016 .

Ciclesonide, a novel inhaled steroid, has no effect on hypothalamic-pituitary-adrenal (HPA)-axis function in mild-to-moderate asthmatics*

S. Rohatagi, C. Laforce, D. Banerji, 2003 .

High doses of the novel inhaled steroid ciclesonide have no effect on HPA-axis function in patients with moderate-to-severe persistent asthma

S. Szefler, S. Rohatagi, D. Banerji, 2003 .

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

J. Wedzicha, N. Roche, J. Vestbo, 2016, The New England journal of medicine.

NVA237 once daily reduces the percentage of patients with exacerbations of COPD and associated hospitalizations: The GLOW1 trial

G. Ferguson, A. D’Urzo, D. Banerji, 2011 .

Indacaterol/glycopyrronium (IND/GLY) improves lung function irrespective of gender baseline differences in patients with COPD: A pooled analysis from the IGNITE Program

K. Kostikas, R. Fogel, S. Fucile, 2016 .

PK/PD of inhaled corticosteroids: The risk/benefit of inhaled ciclesonide

H. Derendorf, R. Nave, S. Rohatagi, 2003 .

Once-Daily QVA149 Demonstrates Superior Outcomes in COPD Patients Previously Treated With Fixed-Dose Long-Acting β 2 -Agonist/Inhaled Corticosteroid (LABA/ICS): The ILLUMINATE Study

V. Alagappan, D. Banerji, Hungta Chen, 2013 .

A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study

J. Wedzicha, M. Decramer, J. Vestbo, 2013 .

Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma.

M. Kaliner, B. Lipworth, H. Kaiser, 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma.

S. Szefler, S. Rohatagi, D. Banerji, 2005, Chest.

Addressing unmet needs in the treatment of COPD

R. Fogel, F. Patalano, P. D’Andrea, 2014, European Respiratory Review.

Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study.

G. Ferguson, F. Patalano, D. Banerji, 2016, Chronic obstructive pulmonary diseases.

FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.

E. Kerwin, D. Mahler, S. Maitra, 2015, American journal of respiratory and critical care medicine.

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD

Nuofu Zhang, N. Zhong, F. Patalano, 2015, International journal of chronic obstructive pulmonary disease.

Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study

M. Decramer, D. Mahler, H. Worth, 2013, European Respiratory Journal.

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study

R. Dahl, D. Jadayel, V. Alagappan, 2013, International journal of chronic obstructive pulmonary disease.

Recent advances in COPD disease management with fixed-dose long-acting combination therapies

J. Wedzicha, E. Bateman, C. Vogelmeier, 2014, Expert review of respiratory medicine.

Patient‐reported Outcomes for the Detection, Quantification, and Evaluation of Chronic Obstructive Pulmonary Disease Exacerbations

J. Wedzicha, F. Martinez, G. Donaldson, 2018, American journal of respiratory and critical care medicine.

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.

E. Bateman, C. Vogelmeier, P. D’Andrea, 2013, The Lancet. Respiratory medicine.

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD

R. Buhl, D. Banerji, 2012, International journal of chronic obstructive pulmonary disease.

Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients

J. Wedzicha, C. Vogelmeier, K. Kostikas, 2020, International journal of chronic obstructive pulmonary disease.

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis

C. Vogelmeier, N. Zhong, R. Fogel, 2016, International journal of chronic obstructive pulmonary disease.

Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program

K. Kostikas, R. Fogel, S. Fucile, 2017, COPD.

Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients.

J. Wedzicha, R. Dahl, R. Buhl, 2014, Respiratory medicine.

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Corrigendum]

R. Dahl, D. Jadayel, V. Alagappan, 2014, International Journal of Chronic Obstructive Pulmonary Disease.

A novel model-based approach for dose determination of glycopyrronium bromide in COPD

D. Renard, M. Gibbs, V. Alagappan, 2012, BMC Pulmonary Medicine.

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study

J. Wedzicha, N. Roche, J. Vestbo, 2018, International journal of chronic obstructive pulmonary disease.

Late-breaking abstract: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: The LANTERN study

Nuofu Zhang, N. Zhong, F. Patalano, 2014 .

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study

J. Wedzicha, A. Anzueto, K. Kostikas, 2018, Respiratory Research.

P191 QVA149 once daily improves exercise tolerance and lung function in patients with moderate to severe COPD: the BRIGHT study

D. Jadayel, P. D’Andrea, J. Beier, 2012, Thorax.

QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD

R. Dahl, P. D’Andrea, V. Alagappan, 2013 .

Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study

D. Mahler, R. Fogel, A. D’Urzo, 2014 .

QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study

J. Wedzicha, M. Decramer, R. Fogel, 2014 .

P192 QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study

D. Banerji, N. Gallagher, M. Henley, 2012, Thorax.

P193 Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study

D. Banerji, N. Gallagher, M. Henley, 2012, Thorax.

P252 Once-daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial

V. Alagappan, D. Banerji, T. Overend, 2011, Thorax.

P253 NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24 h: the GLOW1 trial

V. Alagappan, D. Banerji, T. Overend, 2011, Thorax.

Reply: What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease?

J. Wedzicha, N. Roche, C. Vogelmeier, 2017, American journal of respiratory and critical care medicine.

Comparative dose-ranging study of triamcinolone acetonide inhalation aerosol using propellants hydrofluoroalkane 134a or P-12 in children with chronic asthma

D. Banerji, R. Kane, D. Pearlman, 1999 .

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.

D. Jadayel, S. Korn, P. D’Andrea, 2014, Respiratory medicine.